| Switching from potent cytochrome P450 (CYP) 2D6-inhibiting antidepressants to a weak CYP2D6-inhibiting antidepressant resulted in relevant rises in endoxifen systemic exposures in breast cancer patients. |
| The weak CYP2D6 inhibitor escitalopram seems to be a safe alternative in tamoxifen-treated patients requiring treatment with an antidepressant. |
| The potent CYP2D6-inhibiting antidepressants paroxetine and fluoxetine should be switched to escitalopram in tamoxifen-treated individuals. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.